Horizon Health International Corp.

June 24, 2010 09:30 ET

Horizon Health International Corp. Signs Agreement With Pharmaceutical Corporation

MONTREAL, QUEBEC--(Marketwire - June 24, 2010) - HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS:HZHI) (the Company) signs an agreement with one of the largest Pharmaceutical Companies operating out of Kawasaki-Japan.

Mr. Rocco Di Fruscia, President of Horizon Health International Corp., an emerging specialty pharmaceutical company is pleased to announce that it has signed an agreement for the exclusive rights to market and distribute, within North America, the patented enteric coated formulation of Lactoferrin, on the latest nutraceutical products sold on today's Japanese market, generating sales of over $ 350 Million in Japan.

This agreement is exclusive for the North American market and concerns a patented enteric coated formulation of Bovine Lactoferrin, the main product sold in the nutraceutical market in Japan and developed and patented in recent years by NRL Pharma Inc. 

Mr. Di Fruisca says: "The individuals who have been taking our Lactoferrin, have given us nothing but positive feedback and are highly satisfied with their results"

The Company's business:

HORIZON's Subsidiary 'NRL Pharma Canada Inc.' is an emerging specialty pharmaceutical company that is committed to supply its Patented delivery systems of enteric lactoferrin, and "PEG-lactoferrin." We have already introduced enteric lactoferrin products in the market as a supplemental food and have also undertaken projects to further study these products and increase their pharmaceutical applications. Since 2008, the company's proprietary enteric lactoferrin has already earned top market share amongst all lactoferrin-containing products.

What is Lactoferrin?

Lactoferrin: A multifunctional protein of the transferrin family found in various secretory fluids, such as milk, saliva, tears and nasal secretions. Human colostrum ("first milk") has the highest concentration of Lactoferrin, followed by human milk, then cow milk ("bovine milk").

Initially, all mammals consume maternal milk, their only source of diet. It is believed that this milk contains all the essential nutrients required by neonates for healthy growth, in particular, "colostrum", the first milk secreted from the breast after parturition, which is rich in Lactoferrin and regulates stress response, the immune system, and fat burning in neonates.

Lactoferrin is a multi-functional protein derived from milk. Because of its biological function, Lactoferrin has been widely used as a supplement in products such as infant formula and has a variety of health-care applications. 

Lactoferrin is relatively stable in the gastrointestinal tract in infants but is degraded into peptides and amino acids in adults when administered orally. This limits the use of Lactoferrin in the treatment of geriatric diseases and adult lifestyle-related diseases. NRL Pharma Inc. is the only company in the world that supplies enteric Lactoferrin. The enteric coating is a barrier that controls the location in the digestive system where the Lactoferrin it is absorbed.

Enteric coating technology has enabled an exclusive market share for Lactoferrin supplement, which is highly effective even at a very low dose. 

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products and technological changes, dependence upon third-party suppliers, intellectual property rights, and other risks detailed from time to time in the Company's periodic reports.

Contact Information